• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

软组织未分化肉瘤的基因组学:进展、挑战和机遇。

The genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities.

机构信息

Research Department of Pathology, Cancer Institute, University College London, London, WC1E 6BT, UK.

Research Department of Pathology, Cancer Institute, University College London, London, WC1E 6BT, UK; Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex, HA7 4LP, UK.

出版信息

Semin Cancer Biol. 2020 Apr;61:42-55. doi: 10.1016/j.semcancer.2019.11.009. Epub 2019 Dec 19.

DOI:10.1016/j.semcancer.2019.11.009
PMID:31866474
Abstract

Undifferentiated sarcoma of soft tissue (USTS) are aggressive sarcomas that remain a diagnosis of exclusion and show extreme genomic complexity. Many advances in diagnostic criteria have resulted in several revisions in the definition of this rare cancer type. Recent sequencing efforts have illuminated the nature of the genome complexity and have revealed extensive copy number heterogeneity and multiple evolutionary patterns of development. This review places these recent advances into their historical and translational context and covers the changes in nomenclature, molecular classification, and the promise of personalised medicine.

摘要

未分化软组织肉瘤(USTS)是一种侵袭性肉瘤,其始终是一种排他性诊断,表现出极端的基因组复杂性。在诊断标准方面的许多进展导致了对这种罕见癌症类型定义的几次修订。最近的测序工作阐明了基因组复杂性的本质,并揭示了广泛的拷贝数异质性和多种发育进化模式。本综述将这些最新进展置于其历史和转化背景下,并涵盖了命名法、分子分类的变化以及个性化医疗的前景。

相似文献

1
The genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities.软组织未分化肉瘤的基因组学:进展、挑战和机遇。
Semin Cancer Biol. 2020 Apr;61:42-55. doi: 10.1016/j.semcancer.2019.11.009. Epub 2019 Dec 19.
2
Unravelling undifferentiated soft tissue sarcomas: insights from genomics.解析未分化软组织肉瘤:基因组学的见解
Histopathology. 2022 Jan;80(1):109-121. doi: 10.1111/his.14446.
3
Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.基因组拷贝数变异与儿童肉瘤化疗反应生物标志物的整合。
BMC Med Genomics. 2019 Jan 31;12(Suppl 1):23. doi: 10.1186/s12920-018-0456-5.
4
Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues.伴有BCOR-CCNB3基因融合的原发性肾肉瘤:2例报告,显示与肾透明细胞肉瘤存在组织学重叠,提示肾与软组织中BCOR相关肉瘤之间存在进一步联系。
Am J Surg Pathol. 2017 Dec;41(12):1702-1712. doi: 10.1097/PAS.0000000000000926.
5
MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.MET基因拷贝数改变以及MET和肝细胞生长因子的表达是血管肉瘤和未分化多形性肉瘤的潜在生物标志物。
PLoS One. 2015 Apr 6;10(4):e0120079. doi: 10.1371/journal.pone.0120079. eCollection 2015.
6
Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways.未分化肉瘤通过不同的进化途径发展。
Cancer Cell. 2019 Mar 18;35(3):441-456.e8. doi: 10.1016/j.ccell.2019.02.002.
7
Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.伴有KRAS/PIK3CA突变共存的未分化多形性肉瘤。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8563-7. eCollection 2015.
8
Recent progress in the genomics of soft tissue sarcomas.软组织肉瘤基因组学的最新进展。
Curr Opin Oncol. 2008 Jul;20(4):395-9. doi: 10.1097/CCO.0b013e328302edc0.
9
The pathology of soft tissue sarcomas.软组织肉瘤的病理学。
Radiol Med. 2019 Apr;124(4):266-281. doi: 10.1007/s11547-018-0882-7. Epub 2018 Jun 12.
10
Clinicopathologic considerations: how can we fine tune our approach to sarcoma?临床病理考虑因素:我们如何调整肉瘤的治疗方法?
Semin Oncol. 2011 Oct;38 Suppl 3:S3-18. doi: 10.1053/j.seminoncol.2011.09.001.

引用本文的文献

1
EUS-FNA Diagnosis of Pancreatic Undifferentiated Sarcoma.超声内镜引导下细针穿刺活检诊断胰腺未分化肉瘤
Dig Dis Sci. 2025 Jul;70(7):2233-2236. doi: 10.1007/s10620-025-08987-z. Epub 2025 Mar 26.
2
Soft tissue sarcomas at the single-cell and spatial resolution: new markers and targets.单细胞和空间分辨率下的软组织肉瘤:新的标志物和靶点
Cancer Gene Ther. 2025 Jan;32(1):11-21. doi: 10.1038/s41417-024-00856-7. Epub 2024 Nov 24.
3
Local relapse patterns after preoperative radiotherapy of limb and trunk wall soft tissue sarcomas: Prognostic role of imaging and pathologic response factors.
肢体和躯干壁软组织肉瘤术前放疗后的局部复发模式:影像学和病理反应因素的预后作用。
Clin Transl Radiat Oncol. 2024 Jul 26;48:100825. doi: 10.1016/j.ctro.2024.100825. eCollection 2024 Sep.
4
New established cell lines from undifferentiated pleomorphic sarcoma for in vivo study.从未分化多形性肉瘤中建立的新细胞系,用于体内研究。
BMB Rep. 2023 Apr;56(4):258-264. doi: 10.5483/BMBRep.2022-0209.
5
RIPK3 modulates sarcoma through immune checkpoint HAVCR2.受体相互作用蛋白激酶3(RIPK3)通过免疫检查点蛋白2B4(HAVCR2)调节肉瘤。
Oncol Lett. 2022 Sep 13;24(5):381. doi: 10.3892/ol.2022.13501. eCollection 2022 Nov.
6
Undifferentiated sarcoma of bladder with sarcomatoid carcinoma: A case report.
Urol Case Rep. 2022 Jul 4;44:102154. doi: 10.1016/j.eucr.2022.102154. eCollection 2022 Sep.
7
Large mirror brain metastases from primary undifferentiated sarcoma of the breast: case report and review of the literature.乳腺原始未分化肉瘤大镜状脑转移:病例报告及文献复习。
CNS Oncol. 2022 Jun 1;11(2):CNS85. doi: 10.2217/cns-2022-0001. Epub 2022 May 10.
8
Development of a Novel Immune Infiltration-Related ceRNA Network and Prognostic Model for Sarcoma.一种新型肉瘤免疫浸润相关ceRNA网络及预后模型的构建
Front Cell Dev Biol. 2021 Jul 1;9:652300. doi: 10.3389/fcell.2021.652300. eCollection 2021.
9
Identification of Subtype-Specific Metastasis-Related Genetic Signatures in Sarcoma.肉瘤中特定亚型转移相关基因特征的鉴定
Front Oncol. 2020 Oct 6;10:544956. doi: 10.3389/fonc.2020.544956. eCollection 2020.
10
The Study of Sarcoma Microenvironment Heterogeneity Associated With Prognosis Based on an Immunogenomic Landscape Analysis.基于免疫基因组图谱分析的肉瘤微环境异质性与预后相关性研究
Front Bioeng Biotechnol. 2020 Aug 21;8:1003. doi: 10.3389/fbioe.2020.01003. eCollection 2020.